E-cigarette versus nicotine inhaler: comparing the perceptions and experiences of inhaled nicotine devices.

What Was Tested

Researchers studied Therapeutic nicotine (patch, non-peptide) in this randomized controlled trial publication.

Understanding this paradox could be helpful to determine the potential for e-cigarettes as an alternative to tobacco smoking.

Why It Was Studied

In contrast, the similar U.S.

Food and Drug Administration (FDA)-approved nicotine inhaler is rarely utilized by smokers.

Who Took Part

According to the abstract, 2012 participants were involved.

PubMed indexes the participants as young adults, adults, middle-aged adults and older adults, both men and women.

Thirty-eight participants provided data on product use, perceptions, and experiences.

How the Study Was Run

The researchers set it up as a randomized and crossover study.

Random assignment meant chance, not the researchers, decided who got Therapeutic nicotine (patch, non-peptide) and who got the comparison, which limits bias.

Each person switched between Therapeutic nicotine (patch, non-peptide) and the comparison at some point, usually with a gap in between.

The Modified Cigarette Evaluation Questionnaire (mCEQ) measured satisfaction, reward, and aversion.

Cigarette use was also recorded during the product-use periods.

What Was Measured

PubMed files the paper under topics including Attitude to Health, Electronic Nicotine Delivery Systems, Health Knowledge, Attitudes, Practice, Nebulizers and Vaporizers, New Jersey, Nicotine and Patient Satisfaction.

What This Means in Plain Language

The paper is a randomized and crossover study of Therapeutic nicotine (patch, non-peptide) in 2012 participants.

With several hundred people or more, it is a fairly large study for this kind of research.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2014 (Journal of general internal medicine), a journal based in United States.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.